Findings
========

Opportunistic Prostate-Specific-Antigen testing (PSA) of healthy men started at the beginning of the 1990s and led to a steep increase of prostate cancer incidence \[[@B1]-[@B3]\]. In Austria data on surgical treatment of prostate cancer are available since 1997. The purpose of this paper is to present the correlation between the number of newly detected cases and the number of radical prostatectomies with resection of lymph nodes (RPE) by 5 year age group.

Data on the number of newly detected cases and number of prostatectomies where obtained from Statistics Austria. The data on radical prostatectomies by age group are available since 1997 only. The data set covers the age group 40 to 89 years comprising a population of 1.738,655 men in the year 2000. Since cases are anonymized it is indeterminable whether newly detected cases are operated in the year of diagnosis or in the following year, if ever.

Cases treated by perineal cryosurgery were excluded, due to the small total number (0 to 2 cases per year).

The number of newly detected cases and of RPE (1997 through 2004) as well as the calculated percentage per year by 5 year age group are given in table [1](#T1){ref-type="table"}. The absolute number of prostate cancer cases rose from 3999 in 1997 to 5416 in 2004 (+35.4%, all age groups). The absolute number of RPE rose from 1648 in 1997 to 3200 in 2004 (+94.2%, all age groups). The percentage of RPE in relation to the number of newly detected cases rises from 41% in 1997 to 59% in 2004 (all age groups). The increase of this percentage is observed in all age groups younger than 70 years but not in older age groups, the linear trend over time is significant for all age groups and for totals, except for age group 40--44 years.

###### 

Number of newly detected cases of prostate cancer in Austria, and number of radical prostatectomies 1997--2004, as well as proportion of RPE/incidence, and P value for linear time trend, totals and 5-year age groups of men aged 40--89.

  Age      1997   1998   1999    2000   2001   2002   2003   2004                                                                                                                     
  -------- ------ ------ ------- ------ ------ ------ ------ ------ ------ ------ ------ ----- ------ ------ ------ ------ ------ ------- ------ ------ ------- ------ ------ ------- ----------
           Nndc   RPE    Nndc    RPE    Nndc   RPE    Nndc   RPE    Nndc   RPE    Nndc   RPE   Nndc   RPE    Nndc   RPE                                                               
                                                                                                                                                                                      
           n      n      \%      n      n      \%     n      n      \%     n      n      \%    n      n      \%     n      n      \%      n      n      \%      n      n      \%      P-value
                                                                                                                                                                                      
  40--44   3      4      \>100   5      4      80     5      4      80     16     14     87    18     15     83     17     18     \>100   22     17     77      25     25     100     0.338
  45--49   26     21     81      40     37     92     44     35     80     74     71     96    85     81     95     95     87     92      125    123    98      109    118    \>100   \< 0.001
  50--54   127    99     78      149    118    79     166    157    95     199    171    86    256    240    94     266    259    97      267    279    \>100   254    258    \>100   \< 0.001
  55--59   371    300    61      440    382    87     496    433    87     522    482    92    541    518    96     559    492    88      597    552    92      585    612    \>100   \< 0.001
  60--64   490    369    75      528    359    68     589    454    77     784    688    88    907    798    88     995    884    89      1158   1067   92      1105   980    89      \< 0.001
  65--69   841    515    61      880    568    65     924    560    61     938    666    71    962    685    71     910    651    72      1065   842    79      1011   789    78      \< 0.001
  70--74   837    299    36      873    288    33     976    288    30     1042   355    34    1035   390    38     998    370    37      1074   500    47      1001   377    38      \< 0.001
  75--79   554    34     6       655    31     5      737    38     5      698    40     6     674    42     6      644    26     4       732    119    16      718    36     5       \< 0.001
  80--84   383    4      1       300    2      \<1    316    0      0      333    1      \<1   328    2      \<1    339    0      0       403    38     9       367    2      \<1     \< 0.001
  85--89   367    0      0       348    0      0      340    0      0      317    1      \<1   322    1      \<1    258    0      0       284    15     5       325    1      \<1     \< 0.001
                                                                                                                                                                                      
  Total    3999   1648   41      4218   1826   43     4593   1969   43     4923   2489   51    5128   2774   54     5081   2791   55      5727   3167   55      5416   3200   59      \< 0.001

Nndc \... Number of newly detected cases.

RPE \... Radical Prostatectomy (with resection of lymph nodes).

P-value \... P value for linear time trend.

The increase of the incidence of prostate cancer is well documented for Austria \[[@B1],[@B2]\], however the absolute numbers are for the first time set in relation to the number of RPE nationwide. Within 8 years, the total number of RPE increased by 94.2%, thus nearly doubled, with the increase mainly occurring in the age group 55--69 years. Starting at age 70 years the percentage of RPE remains more or less stable on a substantially lower level.

The number of RPE we used in our calculations represents the official hospital discharge statistics of Austria comprising of the collected data of all hospitals (including private hospitals), but excludes a very small number of self-pay patients. Thus our results negligibly may underestimate the relation of RPE to the number of newly detected cases. A further limitation of our analyses is caused by legal constrains: due to data protection laws we are limited to the use of depersonalized data.

The increase of RPE in Austria can be explained by at least three factors: a) operation technique meliorated significantly, now is a standard procedure, perioperative mortality is low and the risk of postoperative morbidity such as incontinence and erectile dysfunction decreased in Austria \[[@B4],[@B5]\], consequently acceptance of RPE in patients increased. b) By the introduction of PSA testing the target group of prostate cancer screening shifted towards younger age groups, meaning that carcinoma more frequently is sought in younger men \[[@B3]\]. c) Because of the slow progression of most cases, RPE only makes sense when health status permits RPE and patients have a life expectancy of at least 10 years \[[@B6]\].

The high percentage of RPE in men younger than 70 years surely also is influenced by the fact that counselling (towards RPE or radiation therapy) in Austria is performed by urologists. In this context, it is worth mentioning, that the primary intention of this manuscript is to provide the data which can serve as a basis for a constructive discussion about counselling and the provision of the most adequate therapeutic regimes.

The reason for the more or less stable percentage in men aged 70 years or older may lie in the fact that therapy of prostate cancer in these patients more often relies on watchful waiting, active surveillance, external beam radiation, brachytherapy or hormonal treatment. Detailed data for these therapies are not available.

In conclusion, currently 59% of prostate cancer cases detected are treated by RPE, a percentage steadily rising from 1997 on. On one hand, the dramatic increase of RPE already leads to a slight reduction of prostate cancer mortality in Austria \[[@B3],[@B7]\], on the other hand the question of over-testing and over-treatment, and added morbidity remains unanswered and analyses are still pending for Austria.
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